Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 187 results for prostate cancer

  1. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1110.

    Withdrawn guidance

  2. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Withdrawn guidance

  3. Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)

    This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.

    Withdrawn guidance

  4. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  5. Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255)

    This guidance has been updated and replaced by NICE technology appraisal guidance 391.

    Withdrawn guidance

  6. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)

    We have moved interventional procedures guidance 174 to become HealthTech guidance 113. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  8. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  9. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  10. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  11. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Diabetic foot problems: prevention and management (NG19)

    This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

    NICE guideline
    Last updated
    11 October 2019
    View recommendations

    Sections for NG19

  13. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

    Medtech innovation briefing
    Published
    10 June 2016

  14. Thousands could benefit from new take-at-home treatment for advanced prostate cancer

    NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.

    News
    Last updated
    23 January 2026

  15. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE